ICCC Stock Price, ImmuCell Corp Quote, Chart

Market Summary

USD5.000.00

Market Closed

0.00%

ICCC Stock Price

View Fullscreen

ICCC RSI Chart

ICCC Valuation

Market Cap

38.8M

Price/Earnings (Trailing)

-6.71

Price/Sales (Trailing)

2.22

EV/EBITDA

-18.39

Price/Free Cashflow

-5.9

ICCC Price/Sales (Trailing)

ICCC Profitability

EBT Margin

-33.02%

Return on Equity

-23.1%

Return on Assets

-13.18%

Free Cashflow Yield

-16.94%

ICCC Fundamentals

ICCC Revenue

Revenue (TTM)

17.5M

Rev. Growth (Yr)

30.3%

Rev. Growth (Qtr)

-5.57%

ICCC Earnings

Earnings (TTM)

-5.8M

Earnings Growth (Yr)

31.66%

Earnings Growth (Qtr)

-21.26%

Breaking Down ICCC Revenue

Last 7 days

-2.0%

Last 30 days

-4.6%

Last 90 days

-4.4%

Trailing 12 Months

2.0%

How does ICCC drawdown profile look like?

ICCC Financial Health

Current Ratio

2.85

Debt/Equity

0.42

Debt/Cashflow

-0.44

ICCC Investor Care

Shares Dilution (1Y)

0.05%

Diluted EPS (TTM)

-0.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	16.0M	15.7M	16.3M	17.5M
2022	21.1M	20.5M	20.1M	18.6M
2021	14.5M	16.1M	17.5M	19.2M
2020	14.2M	14.5M	15.2M	15.3M
2019	12.5M	12.2M	13.0M	13.7M
2018	9.8M	11.0M	11.2M	11.0M
2017	10.1M	9.5M	9.5M	10.4M
2016	10.1M	10.5M	10.0M	9.5M
2015	8.6M	9.0M	9.7M	10.2M
2014	6.2M	6.4M	7.0M	7.6M
2013	5.5M	5.7M	5.9M	6.0M
2012	5.3M	5.2M	5.3M	5.4M
2011	4.6M	4.8M	4.9M	5.1M
2010	0	4.5M	4.4M	4.4M
2009	0	0	0	4.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ImmuCell Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 06, 2023	tomsche david scott	back to issuer	14,737	4.7541	3,100	-
Mar 14, 2023	tomsche david scott	back to issuer	10,879	5.49451	1,980	-
Mar 13, 2023	tomsche david scott	back to issuer	11,114	5.29281	2,100	-
Sep 12, 2022	tomsche david scott	back to issuer	6,217	7.76217	801	-
Sep 09, 2022	tomsche david scott	back to issuer	5,432	7.76017	700	-
Sep 08, 2022	tomsche david scott	back to issuer	6,970	7.69403	906	-
Jun 14, 2022	tomsche david scott	back to issuer	5,322	8.18846	650	-
Jun 13, 2022	tomsche david scott	back to issuer	11,559	7.78393	1,485	-
Jun 13, 2022	cunningham david	bought	8,000	8.00	1,000	-
Jun 09, 2022	tomsche david scott	back to issuer	12,748	8.49921	1,500	-

Which funds bought or sold ICCC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	MISSION WEALTH MANAGEMENT, LP	sold off	-100	-50,900	-	-%
Apr 25, 2024	Mesirow Financial Investment Management, Inc.	unchanged	-	2,557	64,543	-%
Apr 24, 2024	Essex Financial Services, Inc.	unchanged	-	2,310	58,300	-%
Apr 22, 2024	WEALTH EFFECTS LLC	unchanged	-	3,237	81,710	0.03%
Apr 16, 2024	Prosperity Planning, Inc.	unchanged	-	3,360	84,800	0.03%
Apr 16, 2024	Overbrook Management Corp	unchanged	-	6,900	174,142	0.05%
Mar 11, 2024	VANGUARD GROUP INC	added	0.74	-43,572	1,051,620	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	added	0.15	-491	10,358	-%
Feb 14, 2024	Cresset Asset Management, LLC	unchanged	-	-11,397	523,210	-%

Are Funds Buying or Selling ICCC?

Are funds buying ICCC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ICCC

No. of Funds

Unveiling ImmuCell Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 16, 2021	pessin norman h	9.10%	703,636	SC 13D/A
Feb 04, 2021	wellington management group llp	0.00%	0	SC 13G/A
Feb 03, 2021	wellington trust co n a	0.00%	0	SC 13G/A
Feb 03, 2021	wellington trust company, national association multiple common trust funds trust, micro cap equity p	0.00%	0	SC 13G/A
Jan 29, 2020	wellington trust co n a	9.48%	683,334	SC 13G
Jan 28, 2020	wellington management group llp	9.48%	683,334	SC 13G

Recent SEC filings of ImmuCell Corp

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEF 14A	DEF 14A
Apr 10, 2024	424B2	Prospectus Filed
Apr 10, 2024	424B2	Prospectus Filed
Apr 09, 2024	8-K	Current Report
Apr 09, 2024	8-K	Current Report
Apr 09, 2024	EFFECT	EFFECT
Apr 01, 2024	S-3	S-3
Apr 01, 2024	10-K	Annual Report
Mar 06, 2024	8-K	Current Report
Feb 27, 2024	8-K	Current Report

Peers (Alternatives to ImmuCell Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

ImmuCell Corp News

Latest updates

ImmuCell Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-5.6%	5,096	5,397	3,533	3,447	3,911	4,796	3,861	6,000	5,444	5,150	4,542	4,107	3,743	3,723	2,966	4,910	3,632	2,970	2,710	4,411	2,937
Gross Profit	-0.7%	1,258	1,267	1,044	301	992	1,846	1,707	3,103	2,561	2,419	2,074	1,602	1,621	1,722	1,283	2,236	1,838	1,451	1,249	2,201	1,396
Operating Expenses	-7.7%	2,261	2,451	2,348	2,557	2,626	2,463	2,326	2,533	2,415	2,148	1,859	1,977	2,255	1,974	1,975	2,039	2,081	1,881	1,796	1,936	2,322
S&GA Expenses	-17.9%	672	817	720	879	993	727	659	812	890	656	437	521	660	459	466	583	690	498	524	607	583
R&D Expenses	-4.7%	1,066	1,118	1,100	1,110	1,049	1,270	1,139	1,036	1,090	1,047	1,000	1,031	1,170	1,123	1,087	974	972	985	820	910	1,263
EBITDA Margin	-Infinity%	-0.15*	-	-0.20*	-0.15*	0.02*	0.10*	0.14*	0.17*	0.14*	0.16*	0.14*	0.09*	0.12*	0.08*	-	-	-	-	-	-	-
Interest Expenses	-	141	-	-	-	91.00	88.00	88.00	72.00	74.00	77.00	79.00	79.00	73.00	75.00	76.00	256	96.00	105	108	112	109
Income Taxes	488.6%	1.00	229*	2.00	2.00	2.00	4.00	1.00	1.00	1.00	8.00	-	-	4.00	-	-	-14.63	-3.62	7.00	15.00	9.00	15.00
Earnings Before Taxes	-21.1%	-1,138	-939	-1,378	-2,313	-1,666	-651	-683	514	75.00	156	141	-441	193	-322	-765	-136	-314	-495	-611	154	-1,037
EBT Margin	14.6%	-0.33*	-0.39*	-0.38*	-0.33*	-0.13*	-0.04*	0.00*	0.04*	0.00*	0.00*	-0.03*	-0.09*	-0.07*	-	-	-	-	-	-	-	-
Net Income	-21.3%	-1,139	-940	-1,379	-2,315	-1,667	-655	-684	513	74.00	148	141	-441	189	-322	-765	-122	-310	-502	-627	145	-1,052
Net Income Margin	14.6%	-0.33*	-0.39*	-0.38*	-0.33*	-0.13*	-0.04*	0.00*	0.04*	0.00*	0.00*	-0.03*	-0.09*	-0.07*	-	-	-	-	-	-	-	-
Free Cashflow	13.3%	-804	-928	-1,389	-3,444	-2,788	-1,992	-569	-168	-116	-416	-148	-972	-128	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-1.7%	44.00	45.00	44.00	43.00	45.00	46.00	46.00	47.00	44.00	44.00	44.00	40.00	40.00	40.00	41.00	40.00	39.00	39.00	39.00	40.00	33.00
Current Assets	-100.0%	-	12.00	11.00	12.00	14.00	16.00	17.00	18.00	16.00	16.00	16.00	12.00	12.00	10.00	11.00	11.00	13.00	14.00	14.00	15.00	6.00
Cash Equivalents	-50.8%	1.00	2.00	1.00	3.00	6.00	9.00	11.00	12.00	10.00	10.00	11.00	7.00	7.00	5.00	8.00	8.00	6.00	2.00	1.00	11.00	3.00
Inventory	5.8%	8.00	7.00	8.00	6.00	6.00	5.00	5.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	2.00	2.00	2.00
Net PPE	-2.1%	28.00	28.00	29.00	28.00	28.00	28.00	27.00	27.00	27.00	27.00	27.00	26.00	27.00	27.00	26.00	26.00	25.00	25.00	25.00	26.00	26.00
Goodwill	0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	1.5%	19.00	19.00	17.00	15.00	14.00	14.00	13.00	14.00	12.00	12.00	11.00	12.00	12.00	12.00	12.00	11.00	10.00	10.00	10.00	10.00	11.00
Current Liabilities	26.1%	4.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00
Long Term Debt	-3.3%	11.00	11.00	-	-	9.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-3.9%	25.00	26.00	27.00	28.00	30.00	32.00	33.00	33.00	33.00	32.00	32.00	28.00	28.00	28.00	28.00	29.00	29.00	29.00	30.00	30.00	22.00
Retained Earnings	-10.5%	-12.01	-10.87	-9.93	-8.55	-6.23	-4.56	-3.91	-3.23	-3.74	-3.81	-3.96	-4.10	-3.66	-3.85	-3.53	-2.76	-2.64	-2.33	-1.83	-1.20	-1.34
Additional Paid-In Capital	0.3%	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	23.00
Shares Outstanding	0.1%	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	7.00	7.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	64.00	-	-	-	64.00	-	-	-	30.00	-	-	-	41.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-42.4%	-723	-507	-681	-2,761	-1,297	-1,258	373	639	588	259	731	-623	156	-667	969	857	-46.62	-66.41	-330	677	-138
Share Based Compensation	4.4%	101	96.00	76.00	96.00	65.00	85.00	62.00	54.00	41.00	45.00	23.00	35.00	57.00	62.00	57.00	77.00	92.00	69.00	70.00	83.00	86.00
Cashflow From Investing	106.3%	34.00	-533	-708	-682	-1,490	-734	-943	-796	-703	-671	-879	657	756	-1,473	-2,566	713	4,203	1,340	-8,742	-203	-98.75
Cashflow From Financing	-120.4%	-321	1,576	-251	749	-248	-223	-204	1,790	-194	208	4,042	-176	717	-143	1,296	41.00	-217	-215	-214	7,589	365

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ICCC Income Statement

2023-12-31

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Product sales	$ 17,471,669	$ 18,567,962
Costs of goods sold	13,602,385	10,919,183
Gross margin	3,869,284	7,648,779
Product development expenses	4,394,852	4,493,872
Sales and marketing expenses	3,088,215	3,190,033
Administrative expenses	2,134,295	2,263,817
Operating expenses	9,617,362	9,947,722
NET OPERATING LOSS	(5,748,078)	(2,298,943)
Other expenses, net	21,893	187,190
LOSS BEFORE INCOME TAXES	(5,769,971)	(2,486,133)
Income tax expense	4,627	7,672
NET LOSS	$ (5,774,598)	$ (2,493,805)
Basic weighted average common shares outstanding (in Shares)	7,747,686	7,745,122
Basic net loss per share (in Dollars per share)	$ (0.75)	$ (0.32)
Diluted weighted average common shares outstanding (in Shares)	7,747,686	7,745,122
Diluted net loss per share (in Dollars per share)	$ (0.75)	$ (0.32)

ICCC Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 978,741	$ 5,791,562
Trade accounts receivable	2,185,383	1,758,600
Inventory	7,811,841	6,038,539
Prepaid expenses and other current assets	493,885	406,055
Total current assets	11,469,850	13,994,756
Property, plant and equipment, net	27,575,683	28,441,726
Operating lease right-of-use asset	4,571,149	2,194,670
Goodwill	95,557	95,557
Intangible assets, net	38,208	57,312
Other assets	57,655	76,628
TOTAL ASSETS	43,808,102	44,860,649
CURRENT LIABILITIES:
Current portion of debt obligations	1,428,807	1,039,447
Current portion of operating lease liability	644,276	31,764
Accounts payable and accrued expenses	2,124,337	2,000,862
Total current liabilities	4,197,420	3,072,073
LONG-TERM LIABILITIES:
Debt obligations, net of current portion	10,540,496	9,191,109
Operating lease liability, net of current portion	4,077,109	2,217,418
Total long-term liabilities	14,617,605	11,408,527
TOTAL LIABILITIES	18,815,025	14,480,600
CONTINGENT LIABILITIES AND COMMITMENTS (See Note 11)
STOCKHOLDERS’ EQUITY:
Common stock, $0.10 par value per share, 15,000,000 shares authorized and 7,814,165 shares issued as of both December 31, 2023 and 2022 and 7,750,864 and 7,746,864 shares outstanding as of December 31, 2023 and 2022, respectively	781,417	781,417
Additional paid-in capital	36,357,239	35,978,364
Accumulated deficit	(12,007,097)	(6,232,499)
Treasury stock, at cost, 63,301 and 67,301 shares as of December 31, 2023 and 2022, respectively	(138,482)	(147,233)
Total stockholders’ equity	24,993,077	30,380,049
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 43,808,102	$ 44,860,649

About ImmuCell Corp

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

CEO	Mr. Michael F. Brigham
WEBSITE	https://immucell.com
INDUSTRY	Biotechnology
EMPLOYEES	66

ImmuCell Corp Frequently Asked Questions

What is the ticker symbol for ImmuCell Corp? What does ICCC stand for in stocks?

ICCC is the stock ticker symbol of ImmuCell Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ImmuCell Corp (ICCC)?

As of Thu May 02 2024, market cap of ImmuCell Corp is 38.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICCC stock?

You can check ICCC's fair value in chart for subscribers.

What is the fair value of ICCC stock?

You can check ICCC's fair value in chart for subscribers. The fair value of ImmuCell Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ImmuCell Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ICCC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ImmuCell Corp a good stock to buy?

The fair value guage provides a quick view whether ICCC is over valued or under valued. Whether ImmuCell Corp is cheap or expensive depends on the assumptions which impact ImmuCell Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICCC.

What is ImmuCell Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, ICCC's PE ratio (Price to Earnings) is -6.71 and Price to Sales (PS) ratio is 2.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICCC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ImmuCell Corp's stock?

In the past 10 years, ImmuCell Corp has provided 0.029 (multiply by 100 for percentage) rate of return.